Acta Diabetologica

, Volume 55, Issue 5, pp 449–458 | Cite as

Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes

  • Sudipta Chattopadhyay
  • Anish George
  • Joseph John
  • Thozhukat Sathyapalan
Original Article



We evaluate prevalence of new abnormal glucose tolerance (AGT) in post-MI survivors without known diabetes (DM) if guidelines are followed and compare the ability of admission (APG), fasting (FPG) and 2-h post-load plasma glucose (2h-PG) to predict prognosis.


A total of 674 patients were followed up for 4 years for incidence of major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal re-infarction or non-haemorrhagic stroke. Ability of models including APG, FPG and 2h-PG to predict MACE was compared.


Of the total, 93–96% of impaired glucose tolerance and 64–75% of DM would be missed with current guidelines. MACE was higher in the upper quartiles of 2h-PG. When 2h-PG and FPG were included simultaneously in models, only 2h-PG predicted MACE (HR 1.12, CI 1.04–1.20, p = 0.0012), all cause mortality (HR 1.17, CI 1.05–1.30, p = 0.0039), cardiovascular mortality (HR 1.17, CI 1.02–1.33, p = 0.0205) and non-fatal MI (HR 1.10, CI 1.01–1.20, p = 0.0291). Adding 2h-PG significantly improved ability of models including FPG (χ2 = 16.01, df = 1, p = 0.0001) or FPG and APG (χ2 = 17.36, df = 1, p = 0.000) to predict MACE. Model including 2h-PG only had the lowest Akaike’s information criteria and highest Akaike weights suggesting that this was the best in predicting events. Adding 2h-PG to models including FPG or APG with other co-variates yielded continuous net reclassification improvement (NRI) of 0.22 (p = 0.026) and 0.27 (p = 0.005) and categorical NRI of 0.09 (p = 0.032) and 0.12 (p = 0.014), respectively. Adding 2 h-PG to models including only FPG, only APG and both yielded integrated discrimination improvement of 0.012 (p = 0.015), 0.022 (p = 0.001) and 0.013 (p = 0.014), respectively.


AGT is under-diagnosed on current guidelines. 2h-PG is a better predictor of prognosis compared to APG and FPG.


Diabetes Myocardial infarction Acute coronary syndrome Oral glucose tolerance Impaired glucose tolerance Prognosis Glycated haemoglobin Glycosylated haemoglobin 


Compliance with ethical standards

Conflict of interest

The authors declare they have no conflict of interest.

Ethical approval

All procedures performed in study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study formal consent is not required.

Supplementary material

592_2018_1114_MOESM1_ESM.pdf (112 kb)
Supplementary material 1 (PDF 112 kb)


  1. 1.
    National Institute for Health and Care Excellence. Clinical guideline [CG130]: Hyperglycaemia in acute coronary syndromes: management. https://www.niceorguk/guidance/cg130
  2. 2.
    Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087CrossRefPubMedGoogle Scholar
  3. 3.
    Senthinathan A, Kelly V, Dzingina M et al (2011) Hyperglycaemia in acute coronary syndromes: summary of NICE guidance. BMJ 343:d6646CrossRefPubMedGoogle Scholar
  4. 4.
    Bartnik M, Ryden L, Malmberg K et al (2007) Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 93:72–77CrossRefPubMedGoogle Scholar
  5. 5.
    de Mulder M, Oemrawsingh RM, Stam F, Boersma E, Umans VA (2012) Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. Heart 98:37–41CrossRefPubMedGoogle Scholar
  6. 6.
    Hage C, Lundman P, Ryden L, Mellbin L (2013) Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes. Eur J Prev Cardiol 20:549–554CrossRefPubMedGoogle Scholar
  7. 7.
    Doerr R, Hoffmann U, Otter W et al (2011) Oral glucose tolerance test and HbA(1)c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study. Diabetologia 54:2923–2930CrossRefPubMedGoogle Scholar
  8. 8.
    Tenerz A, Nilsson G, Forberg R et al (2003) Basal glucometabolic status has an impact on long-term prognosis following an acute myocardial infarction in non-diabetic patients. J Intern Med 254:494–503CrossRefPubMedGoogle Scholar
  9. 9.
    Timmer JR, Hoekstra M, Nijsten MW et al (2011) Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 124:704–711CrossRefPubMedGoogle Scholar
  10. 10.
    Pararajasingam G, Hofsten DE, Logstrup BB et al (2016) Newly detected abnormal glucose regulation and long-term prognosis after acute myocardial infarction: Comparison of an oral glucose tolerance test and glycosylated haemoglobin A1c. Int J Cardiol 214:310–315CrossRefPubMedGoogle Scholar
  11. 11.
    Aggarwal B, Shah GK, Randhawa M et al (2016) Utility of glycated hemoglobin for assessment of glucose metabolism in patients with ST-segment elevation myocardial infarction. Am J Cardiol 117:749–753CrossRefPubMedGoogle Scholar
  12. 12.
    Gustafsson I, Kistorp CN, James MK et al (2007) Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. Am Heart J 154:470–476CrossRefPubMedGoogle Scholar
  13. 13.
    Kitada S, Otsuka Y, Kokubu N et al (2010) Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc Diabetol 9:75CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tamita K, Katayama M, Takagi T et al (2007) Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J 71:834–841CrossRefPubMedGoogle Scholar
  15. 15.
    Bartnik M, Malmberg K, Norhammar A et al (2004) Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 25:1990–1997CrossRefPubMedGoogle Scholar
  16. 16.
    Knudsen EC, Seljeflot I, Abdelnoor M et al (2011) Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: a follow-up study. BMC Endocr Disord 11:14CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    George A, Bhatia RT, Buchanan GL et al (2015) Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PLoS ONE 10:e0142045CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lenzen M, Ryden L, Ohrvik J et al (2006) Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 27:2969–2974CrossRefPubMedGoogle Scholar
  19. 19.
    Tamita K, Katayama M, Takagi T et al (2012) Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations. Heart 98:848–854CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mazurek M, Kowalczyk J, Lenarczyk R et al (2012) The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol 11:78CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ritsinger V, Tanoglidi E, Malmberg K et al (2014) Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diabetes Vasc Dis Res 12:23CrossRefGoogle Scholar
  22. 22.
    Thygesen K, Alpert JS, White HD (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538CrossRefPubMedGoogle Scholar
  23. 23.
    Ryden L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136CrossRefPubMedGoogle Scholar
  24. 24.
    American Diabetes Association (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197CrossRefGoogle Scholar
  25. 25.
    Genuth S, Alberti KG, Bennett P et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRefPubMedGoogle Scholar
  26. 26.
    American Diabetes Association (2012) Standards of medical care in diabetes–2012. Diabetes Care 35(Suppl 1):S11–S63Google Scholar
  27. 27.
    Y Sakamoto, M Ishiguro, G Kitagawa (1986) Akaike information criterion statistics. Springer, NetherlandsGoogle Scholar
  28. 28.
    Wagenmakers EJ, Farrell S (2004) AIC model selection using Akaike weights. Psychon Bull Rev 11:192–196CrossRefPubMedGoogle Scholar
  29. 29.
    Bartnik M, Ryden L, Ferrari R et al (2004) The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25:1880–1890CrossRefPubMedGoogle Scholar
  30. 30.
    Norhammar A, Tenerz A, Nilsson G et al (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140–2144CrossRefPubMedGoogle Scholar
  31. 31.
    The DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRefGoogle Scholar
  32. 32.
    Knudsen EC, Seljeflot I, Abdelnoor M et al (2009) Abnormal glucose regulation in patients with acute ST-elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol 8:6CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Suleiman M, Hammerman H, Boulos M et al (2005) Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 111:754–760CrossRefPubMedGoogle Scholar
  34. 34.
    Avezum A, Makdisse M, Spencer F et al (2005) Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149:67–73CrossRefPubMedGoogle Scholar
  35. 35.
    Mandelzweig L, Battler A, Boyko V et al (2006) The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 27:2285–2293CrossRefPubMedGoogle Scholar
  36. 36.
    Smith NL, Barzilay JI, Shaffer D et al (2002) Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 162:209–216CrossRefPubMedGoogle Scholar
  37. 37.
    Qiao Q, Pyorala K, Pyorala M et al (2002) Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 23:1267–1275CrossRefPubMedGoogle Scholar
  38. 38.
    Sinnaeve PR, Steg PG, Fox KA et al (2009) Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med 169:402–409CrossRefPubMedGoogle Scholar
  39. 39.
    Ravid M, Berkowicz M, Sohar E (1975) Hyperglycemia during acute myocardial infarction. A six-year follow-up study. JAMA 233:807–809CrossRefPubMedGoogle Scholar
  40. 40.
    Ando T, Okada S, Niijima Y et al (2010) Impaired glucose tolerance, but not impaired fasting glucose, is a risk factor for early-stage atherosclerosis. Diabet Med 27:1430–1435CrossRefPubMedGoogle Scholar
  41. 41.
    Choi ES, Rhee EJ, Choi JH et al (2010) The association of brachial-ankle pulse wave velocity with 30-minute post-challenge plasma glucose levels in korean adults with no history of type 2 diabetes. Korean Diabetes J 34:287–293CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Mellen PB, Bittner V, Herrington DM (2007) Post-challenge glucose predicts coronary atherosclerotic progression in non-diabetic, post-menopausal women. Diabet Med 24:1156–1159CrossRefPubMedGoogle Scholar
  43. 43.
    Hanefeld M, Koehler C, Henkel E et al (2000) Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. Diabet Med 17:835–840CrossRefPubMedGoogle Scholar
  44. 44.
    Temelkova-Kurktschiev TS, Koehler C, Henkel E et al (2000) Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23:1830–1834CrossRefPubMedGoogle Scholar
  45. 45.
    Wallander M, Malmberg K, Norhammar A, Ryden L, Tenerz A (2008) Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 31:36–38CrossRefPubMedGoogle Scholar
  46. 46.
    Tenerz A, Norhammar A, Silveira A et al (2003) Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 26:2770–2776CrossRefPubMedGoogle Scholar
  47. 47.
    Hage C, Malmberg K, Ryden L, Wallander M (2010) The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. Int J Cardiol 145:259–260CrossRefPubMedGoogle Scholar
  48. 48.
    Moura FA, Figueiredo VN, Teles BS et al (2015) Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 243:124–130CrossRefPubMedGoogle Scholar
  49. 49.
    Liu XJ, Wan ZF, Zhao N et al (2015) Adjustment of the GRACE score by Hemoglobin A1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coronary intervention. Cardiovasc Diabetol 19:110CrossRefGoogle Scholar
  50. 50.
    Geng J, Zhang Y, Wang B et al (2017) Glycosylated hemoglobin levels and clinical outcomes in nondiabetic patients with coronary artery disease: a meta-analysis. Medicine (Baltimore) 96:e6784CrossRefGoogle Scholar
  51. 51.
    Shin D, Ahn J, Cha KS et al (2016) Impact of initial glycosylated hemoglobin level on cardiovascular outcomes in prediabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 27:40–46CrossRefPubMedGoogle Scholar
  52. 52.
    Lazzeri C, Valente S, Chiostri M et al (2015) Glycated haemoglobin and long-term mortality in patients with ST Elevation Myocardial Infarction. J Cardiovasc Med (Hagerstown) 16:404–408CrossRefGoogle Scholar
  53. 53.
    Shahim B, De Bacquer D, De Backer G et al (2017) The prognostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with coronary artery disease: a report from EUROASPIRE IV—a survey from the European Society of Cardiology. Diabetes Care 40:1233–1240CrossRefPubMedGoogle Scholar
  54. 54.
    Tailakh MA, Friger M, Zahger D et al (2017) Prospective study of the impact of diabetes mellitus newly diagnosed by glycated hemoglobin on outcomes in patients undergoing percutaneous coronary intervention. Eur J Intern Med 37:69–74CrossRefPubMedGoogle Scholar
  55. 55.
    Kowalczyk J, Mazurek M, Zielinska T et al (2015) Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol 22:798–806CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Sudipta Chattopadhyay
    • 1
  • Anish George
    • 2
  • Joseph John
    • 3
  • Thozhukat Sathyapalan
    • 4
  1. 1.Department of CardiologyMilton Keynes University HospitalMilton KeynesUK
  2. 2.Department of CardiologyScunthorpe General HospitalScunthorpeUK
  3. 3.Department of CardiologyCastle Hill HospitalKingston upon HullUK
  4. 4.Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical SchoolUniversity of HullKingston upon HullUK

Personalised recommendations